The offer to take Opmedic Group private is fair, says Industrial Alliance

Earlier this month, in an effort to solidify its presence outside of Quebec, Opmedic announced it had acquired a majority stake in Heartland Medical Corporation and Heartland Fertility and Gynecology Clinic, which operates a well-established fertility clinic in the city of Winnipeg.

Opmedic Group’s (Opmedic Group Stock Quote, Chart, News: TSX:OMG) minority shareholders should accept the deal tabled by its founders to go private, says Industrial Alliance analyst Steve Li.

Yesterday, Opmedic announced it had entered into an agreement with a newly formed corporation owned by founders Dr. Pierre St-Michel, Dr. Marc Villeneuve and Dr. Jean-Yves Fontaine, to take Opmedic private for $18.1-million, or $2.90 in cash per share.

The founders own more than two-thirds of Opmedic’s outstanding shares, while institutional investors own approximately 20%. The transaction requires 50% support from minority shareholders.

The founders said the company could operate more efficiently away from the public markets.

“A privatized Opmedic Group will result in lower operating costs and enable management to focus on pursuing the corporation’s business strategy of providing quality patient care at its clinics, and enhance our ability to attract and retain quality health care professionals,” said St-Michel.

Earlier this month, in an effort to solidify its presence outside of Quebec, Opmedic announced it had acquired a majority stake in Heartland Medical Corporation and Heartland Fertility and Gynecology Clinic, which operates a well-established fertility clinic in the city of Winnipeg. The clinic represented Opmedic’s third location outside Quebec and its first in Manitoba.

Yesterday’s offer is a 23.4% premium to last Friday’s closing price and a 20.3% premium to the 20-day volume-weighted average price.

Li says despite the fact that Opmedic Group is a leader in the fertility market, it has been challenged to produce growth for several quarters running. He says that while catalysts such as a consolidation in the fertility clinic market and a ramping up of its Ontario clinics could stimulate growth, the transaction is fair and the risks of the takeout transaction being rejected are low.

In a research update to clients this morning, Li dropped his target price from $3.00 to $2.90 to reflect the takeout offer. The Industrial Alliance analyst recommends that investors tender their shares to the offer.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: omg
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

JUSH stock is a buy, Beacon says

With its first quarter results on deck, Beacon Securities analyst Russell Stanley thinks Jushi Holdings (Jushi Holdings Stock Quote, Chart,… [Read More]

18 mins ago

Is Curaleaf stock still a buy?

The stock has been a steady climber since last October, but ahead of earnings is Curaleaf (Curaleaf Stock Quote, Chart,… [Read More]

3 hours ago

OpenText price target cut at National Bank

Following third quarter results he describes as "in-line", National Bank Financial analyst Richard Tse has cut his price target on… [Read More]

3 hours ago

Silicon Motion stock still a buy, Roth says

Following the company's first quarter results, Roth MKM analyst Suji Desilava remains bullish on Silicon Motion Technology (Silicon Motion Technology… [Read More]

4 hours ago

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

3 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

3 days ago